



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Jun Liang
✉ liang23400@163.com

SPECIALTY SECTION
This article was submitted to
Cancer Immunity
and Immunotherapy,
a section of the journal
Frontiers in Immunology

RECEIVED 25 March 2023
ACCEPTED 30 March 2023
PUBLISHED 11 April 2023

CITATION
Xu T, Liu Y, Lu X and Liang J (2023)
Corrigendum: Toxicity profile of combined
immune checkpoint inhibitors and thoracic
radiotherapy in esophageal cancer: A
meta-analysis and systematic review.
Front. Immunol. 14:1193710.
doi: 10.3389/fimmu.2023.1193710

COPYRIGHT
© 2023 Xu, Liu, Lu and Liang. This is an
open-access article distributed under the
terms of the [Creative Commons Attribution
License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that
the original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.

Corrigendum: Toxicity profile of combined immune checkpoint inhibitors and thoracic radiotherapy in esophageal cancer: A meta-analysis and systematic review

Tongzhen Xu¹, Yunsong Liu¹, Xiaotong Lu¹ and Jun Liang^{2*}

¹Department of Radiotherapy Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ²Department of Radiotherapy Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China

KEYWORDS

esophageal cancer, safety, toxicity profile, immune checkpoint inhibitors, thoracic radiotherapy, systemic analysis

A corrigendum on

Toxicity profile of combined immune checkpoint inhibitors and thoracic radiotherapy in esophageal cancer: A meta-analysis and systematic review

by Xu T, Liu Y, Lu X and Liang J (2022) *Front. Immunol.* 13:1039020. doi: 10.3389/fimmu.2022.1039020

In the published article, there was an error. Two words were misspelled. A correction has been made to **Conclusions**, Paragraph One. This sentence previously stated:

“Compared with PD-1 inhibitors, PD-L1 inhibitors might increase the incidence of any-grade pneumonitis.”

The corrected sentence appears below:

“Compared with PD-L1 inhibitors, PD-1 inhibitors might increase the incidence of any-grade pneumonitis.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.